These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 3882058)

  • 21. Effect of bezafibrate during 4.5 years of treatment of hyperlipoproteinaemia.
    Olsson AG; Lang PD; Vollmar J
    Atherosclerosis; 1985 May; 55(2):195-203. PubMed ID: 4004990
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Changes in lipid and lipoprotein levels and Achilles tendon diameters and indices in familial hypercholesterolaemic patients with tendinous xanthomatosis treated by diet and bezafibrate for 2 years.
    Rouffy J; Chanu B; Bakir R; Goy-Loeper J; Djian F; Monsuez JJ; Gomberg R; Laval-Jeantet M
    Curr Med Res Opin; 1988; 11(2):123-32. PubMed ID: 3219880
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of synvinolin (MK-733) on plasma lipids in familial hypercholesterolaemia.
    Mol MJ; Erkelens DW; Leuven JA; Schouten JA; Stalenhoef AF
    Lancet; 1986 Oct; 2(8513):936-9. PubMed ID: 2877129
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Changes in serum lipoprotein pattern following bezafibrate. Differential effects in type IIa and in type IIb hyperlipoproteinemic patients.
    Sommariva D; Tirrito M; Bonfiglioli D; Pogliaghi I; Branchi A; Ottomano C; Bellintani L
    Pharmacol Res Commun; 1985 Dec; 17(12):1181-91. PubMed ID: 4095126
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of probucol on plasma cholesterol, high and low density lipoprotein cholesterol, and apolipoproteins A1 and A2 in adults with primary familial hypercholesterolemia.
    Mellies MJ; Gartside PS; Glatfelter L; Vink P; Guy G; Schonfeld G; Glueck CJ
    Metabolism; 1980 Oct; 29(10):956-64. PubMed ID: 6999291
    [No Abstract]   [Full Text] [Related]  

  • 26. [Comparison of the lipid-lowering agents clofibrate and bezafibrate in patients with hyperlipoproteinemias IIa and IIb].
    Kokot F; Szczechowska E
    Z Gesamte Inn Med; 1981 Jul; 36(13):454-7. PubMed ID: 7025475
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT study). Fluvastatin Alone and in Combination Treatment.
    Cortellaro M; Cofrancesco E; Boschetti C; Cortellaro F; Mancini M; Mariani M; Paoletti R
    Thromb Haemost; 2000 Apr; 83(4):549-53. PubMed ID: 10780315
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of familial hypercholesterolaemia. United Kingdom lipid clinics study of pravastatin and cholestyramine.
    Betteridge DJ; Bhatnager D; Bing RF; Durrington PN; Evans GR; Flax H; Jay RH; Lewis-Barned N; Mann J; Matthews DR
    BMJ; 1992 May; 304(6838):1335-8. PubMed ID: 1611329
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Evaluation of apoproteins A and B, lipoproteins and plasma lipids during treatment with bezafibrate in various forms of hyperlipoproteinemia].
    Saitta A; Bonaiuto M; Lanzafame F; Mileto A; Pernice F; Cinquegrani M; Mazza G; Micali G; Pangallo A; Fodale P
    Clin Ter; 1988 Mar; 124(5):373-81. PubMed ID: 2974348
    [No Abstract]   [Full Text] [Related]  

  • 30. Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial).
    Goldbourt U; Behar S; Reicher-Reiss H; Agmon J; Kaplinsky E; Graff E; Kishon Y; Caspi A; Weisbort J; Mandelzweig L
    Am J Cardiol; 1993 Apr; 71(11):909-15. PubMed ID: 8465780
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Abnormalities in very low, low and high density lipoproteins in hypertriglyceridemia. Reversal toward normal with bezafibrate treatment.
    Eisenberg S; Gavish D; Oschry Y; Fainaru M; Deckelbaum RJ
    J Clin Invest; 1984 Aug; 74(2):470-82. PubMed ID: 6378975
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Changes in the concentration and composition of lipids and lipoproteins in primary hyperlipoproteinemia during treatment with bezafibrate.
    Hutt V; Wechsler JG; Klör HU; Ditschuneit H
    Arzneimittelforschung; 1983; 33(8):1185-90. PubMed ID: 6685498
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Double-blind placebo-controlled study of the effects of bezafibrate on blood lipids, lipoproteins, and fibrinogen in hyperlipidaemic type 1 diabetes mellitus.
    Winocour PH; Durrington PN; Bhatnagar D; Ishola M; Arrol S; Lalor BC; Anderson DC
    Diabet Med; 1990; 7(8):736-43. PubMed ID: 2147637
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of the efficacy and tolerance of a garlic preparation vs. bezafibrate.
    Holzgartner H; Schmidt U; Kuhn U
    Arzneimittelforschung; 1992 Dec; 42(12):1473-7. PubMed ID: 1288512
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of severe, resistant familial combined hyperlipidemia with a bezafibrate-lovastatin combination.
    Yeshurun D; Abukarshin R; Elias N; Lanir A; Naschitz JE
    Clin Ther; 1993; 15(2):355-63. PubMed ID: 8519043
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of bezafibrate, fenofibrate, nicotinic acid and etofibrate on plasma high-density lipoprotein levels.
    Paoletti R; Franceschini G; Sirtori CR
    Am J Cardiol; 1983 Aug; 52(4):21B-27B. PubMed ID: 6351577
    [No Abstract]   [Full Text] [Related]  

  • 37. Therapeutic effects of bezafibrate and gemfibrozil in hyperlipoproteinaemia type IIa and IIb.
    Kremer P; Marowski C; Jones C; Acacia E
    Curr Med Res Opin; 1989; 11(5):293-303. PubMed ID: 2702851
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical results with gemfibrozil and background to the Helsinki Heart Study.
    Manninen V
    Am J Cardiol; 1983 Aug; 52(4):35B-38B. PubMed ID: 6351578
    [No Abstract]   [Full Text] [Related]  

  • 39. Hypolipidemic effects of bezafibrate: studies in Italy.
    Postiglione A; Riccardi G; Saldalamacchia G
    Monogr Atheroscler; 1986; 14():198-202. PubMed ID: 3526125
    [No Abstract]   [Full Text] [Related]  

  • 40. [Effect of lipanthyl on parameters of lipid metabolism in patients with primary hyperlipoproteinemia].
    Sznajd J; Magdoń M; Idzior B; Konarska R; Malczewska M; Czarnecka H
    Przegl Lek; 1984; 41(2):217-21. PubMed ID: 6377392
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.